Immunotherapy with immunological checkpoint inhibitors (ICIs), cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), and PD-ligand 1 (PD-L1) have demonstrated impressive clinical efficacy in patients with sarcoma [13, 14]. Here, PDCD1 is linked to sarcoma.